Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bonner

Showing results (281-290 of 318) with videos related to

Pageof 32
Sort By:
Head & Neck|January 26, 2022
Factors associated with loss to follow-up after radiation therapy for head and neck cancerJohn M Hoyle, Tanya A Correya, Kelly Kenzik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerF Robert, M P Ezekiel, S A Spencer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 26, 2018
Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future AspirationsRochelle D Jones, Christina H Chapman, Emma B Holliday, et al.
The Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 11, 2002
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plotJeff A Sloan, Daniel J Sargent, Jed Lindman, et al.
Cancer|April 27, 2005
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlySteven E Schild, Philip J Stella, Burke J Brooks, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
MDS-associated <i>SF3B1</i> mutations promote aberrant fate choice of hematopoietic stem cell via mis-splicing of mediator kinase module component CDK8Elizabeth A Bonner, Tun-Yun Hsueh, Axia Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)Steven E Schild, James A Bonner, Shauna Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Significance of neuron-specific enolase levels before and during therapy for small cell lung cancerJ A Bonner, J A Sloan, K M Rowland, et al.
Nature Communications|August 25, 2022
Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signalingHongxing Shen, Fengyuan Huang, Xiangmin Zhang, et al.
Pageof 32

Showing results (281-290 of 318) with videos related to

Sort By:
Pageof 32
Head & Neck|January 26, 2022
Factors associated with loss to follow-up after radiation therapy for head and neck cancerJohn M Hoyle, Tanya A Correya, Kelly Kenzik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerF Robert, M P Ezekiel, S A Spencer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 26, 2018
Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future AspirationsRochelle D Jones, Christina H Chapman, Emma B Holliday, et al.
The Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 11, 2002
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plotJeff A Sloan, Daniel J Sargent, Jed Lindman, et al.
Cancer|April 27, 2005
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlySteven E Schild, Philip J Stella, Burke J Brooks, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
MDS-associated <i>SF3B1</i> mutations promote aberrant fate choice of hematopoietic stem cell via mis-splicing of mediator kinase module component CDK8Elizabeth A Bonner, Tun-Yun Hsueh, Axia Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)Steven E Schild, James A Bonner, Shauna Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Significance of neuron-specific enolase levels before and during therapy for small cell lung cancerJ A Bonner, J A Sloan, K M Rowland, et al.
Nature Communications|August 25, 2022
Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signalingHongxing Shen, Fengyuan Huang, Xiangmin Zhang, et al.
Pageof 32